Señales en vivo de BIAFW | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 jun 2024 @ 16:00):
Our systems believe the stock currently is undervalued by 0.18% compare to its pairs and should correct upwards.

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment...

Stats
Volumen de hoy	1
Volumen promedio	0
Capitalización de mercado	6.18M
EPS	$-0.200 ( Q1 \| 2024-05-15 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0 (Sector) 42.63 (Industry) 39.71
ATR14	$0 (0.00%)

AWH -23.31%

BIAF 1.05%

BIAFW 6.00%

INBS -3.99%

LMDXW 0.00%

PRE 0.00%

PRENW 57.01%

Insider Trading

Date	Person	Action	Amount	type
2023-12-01	Platt Jamie	Buy	0
2023-09-18	Joyce Roby	Buy	0	Common Stock
2021-11-22	Joyce Roby	Buy	14 285	Warrant
2023-09-18	Reveles Xavier Trinidad	Sell	0	Common Stock
2021-08-26	Reveles Xavier Trinidad	Sell	2 142	Stock Option (Right to Buy)

INSIDER POWER
63.76
Last 96 transactions
Buy: 1 799 574 \| Sell: 997 504

Correlación (AI algo v.1.1b): Undervalued: 0.18% $0.531 paired level. (El Algoritmo Rastrea Los Cambios De Las Acciones Más Correlacionadas En Tiempo Real Y Proporciona Una Actualización Instantánea)

bioAffinity Technologies, Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

bioAffinity Technologies, Finanzas

Annual	2023
Ingresos:	$2.53M
Beneficio Bruto:	$542 023 (21.40 %)
EPS:	$-0.910

FY	2023
Ingresos:	$2.53M
Beneficio Bruto:	$542 023 (21.40 %)
EPS:	$-0.910

FY	2022
Ingresos:	$4 803.00
Beneficio Bruto:	$4 336.00 (90.28 %)
EPS:	$-1.810

Financial Reports:

No articles found.

bioAffinity Technologies, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

bioAffinity Technologies,

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.